The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
Open accessAbstract
Anti-CD3 monoclonal antibodies suppress immune responses by transient T-cell depletion and antigenic modulation of the CD3/T-cell receptor complex. Anti-CD3 treatment of adult nonobese diabetic (NOD) mice, a spontaneous model of T-cell-mediated autoimmune insulin-dependent diabetes mellitus, significantly inhibits the autoimmune process. Short-term low-dose anti-CD3 treatment (5 micrograms/day i.v. for 5 consecutive days) prevented the occurrence of an accelerated form of the disease induced by cyclophosphamide. More unexpectedly, when applied to adult NOD females within 7 days of the onset of full-blown diabetes, the same anti-CD3 regimen induced a complete remission of overt disease (i.e., a return to permanent normoglycemia) in 64-80% of mice. This remission was durable (> 4 months) and was not associated with the disappearance of insulitis (mononuclear cell infiltration of the islets). The immunosuppression was apparently specific for beta-cell-associated antigens, since mice showing anti-CD3-induced remission rejected histoincompatible skin grafts normally, whereas they did not destroy syngeneic islet grafts, unlike control untreated overtly diabetic NOD females. These results open major therapeutic perspectives. They strongly suggest that self-tolerance can be restored in adult mice once autoimmunity is fully established and confirm that this effect can be obtained by transient targeting of the CD3/T-cell receptor without massive T-cell debulking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a monoclonal antibody specific for a murine T3 polypeptide.
Leo, O., Foo, M., Sachs, D. H., Samelson, L. E., & Bluestone, J. A. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.5.1374 · Cited by 1,593
"Infectious" Transplantation Tolerance
Qin, S., Cobbold, S. P., Pope, H., Elliott, J., Kioussis, D., Davies, J., & Waldmann, H. (1993) · Science · doi:10.1126/science.8094901 · Cited by 871
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
Cobbold, S. P., Jayasuriya, A., Nash, A., Prospero, T. D., & Waldmann, H. (1984) · Nature · doi:10.1038/312548a0 · Cited by 863
Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat
Castano, L., & Eisenbarth, G. S. (1990) · Annual Review of Immunology · doi:10.1146/annurev.iy.08.040190.003243 · Cited by 644
Bendelac, A., Carnaud, C., Boitard, C., & Bach, J. F. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.4.823 · Cited by 569
Self-citationImmunotherapy of the Nonobese Diabetic Mouse: Treatment with an Antibody to T-Helper Lymphocytes
Shizuru, J. A., Taylor-Edwards, C., Banks, B. A., Gregory, A. K., & Fathman, C. G. (1988) · Science · doi:10.1126/science.2966437 · Cited by 345
Induction of classical transplantation tolerance in the adult.
Qin, S. X., Cobbold, S., Benjamin, R., & Waldmann, H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.3.779 · Cited by 317
Shah, S. C., Malone, J., & Simpson, N. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903023200902 · Cited by 317
Ferran, C., Sheehan, K., Dy, M., Schreiber, R., Merite, S., Landais, P., Noel, L., Grau, G., Bluestone, J., Bach, J., et al. (1990) · European Journal of Immunology · doi:10.1002/eji.1830200308 · Cited by 264
Self-citationT cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice.
Boitard, C., Yasunami, R., Dardenne, M., & Bach, J. F. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.5.1669 · Cited by 256
Self-citation
Cited by
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Tedgui, A., & Mallat, Z. (2006) · Physiological Reviews · doi:10.1152/physrev.00024.2005 · Cited by 1,701
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes
Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902226 · Cited by 1,189
Insulin-Dependent Diabetes Mellitus
Tisch, R., & McDevitt, H. (1996) · Cell · doi:10.1016/s0092-8674(00)81106-x · Cited by 1,150
THE NOD MOUSE: A Model of Immune Dysregulation
Anderson, M. S., & Bluestone, J. A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115643 · Cited by 1,113
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Self-citationType 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies
Van Belle, T. L., Coppieters, K. T., & Von Herrath, M. G. (2011) · Physiological Reviews · doi:10.1152/physrev.00003.2010 · Cited by 1,022
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
Mesenchymal-Stem-Cell-Induced Immunoregulation Involves FAS-Ligand-/FAS-Mediated T Cell Apoptosis
Akiyama, K., Chen, C., Wang, D., Xu, X., Qu, C., Yamaza, T., Cai, T., Chen, W., Sun, L., & Shi, S. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.03.007 · Cited by 705
Herold, K. C., Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D. M., & Bluestone, J. A. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1763 · Cited by 634
Recovery from diabetes in mice by β cell regeneration
Nir, T., Melton, D. A., & Dor, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32959 · Cited by 595
Belghith, M., Bluestone, J. A., Barriot, S., Mégret, J., Bach, J.-F., & Chatenoud, L. (2003) · Nature Medicine · doi:10.1038/nm924 · Cited by 586
Self-citationLenschow, D. J., Ho, S. C., Sattar, H., Rhee, L., Gray, G., Nabavi, N., Herold, K. C., & Bluestone, J. A. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.3.1145 · Cited by 583
Immune cell crosstalk in type 1 diabetes
Lehuen, A., Diana, J., Zaccone, P., & Cooke, A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2787 · Cited by 476
Kamanaka, M., Kim, S. T., Wan, Y. Y., Sutterwala, F. S., Lara-Tejero, M., Galán, J. E., Harhaj, E., & Flavell, R. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.09.013 · Cited by 390
CD3-specific antibodies: a portal to the treatment of autoimmunity
Chatenoud, L., & Bluestone, J. A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2134 · Cited by 388
Self-citationClinical islet transplantation: advances and immunological challenges
Ricordi, C., & Strom, T. B. (2004) · Nature Reviews Immunology · doi:10.1038/nri1332 · Cited by 368
Hering, B. J., Kandaswamy, R., Harmon, J. V., Ansite, J. D., Clemmings, S. M., Sakai, T., Paraskevas, S., Eckman, P. M., Sageshima, J., Nakano, M., et al. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00351.x · Cited by 367
Tarbell, K. V., Petit, L., Zuo, X., Toy, P., Luo, X., Mqadmi, A., Yang, H., Suthanthiran, M., Mojsov, S., & Steinman, R. M. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061631 · Cited by 342
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway
Fife, B. T., Guleria, I., Gubbels Bupp, M., Eagar, T. N., Tang, Q., Bour-Jordan, H., Yagita, H., Azuma, M., Sayegh, M. H., & Bluestone, J. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061577 · Cited by 325
A Comprehensive Review of Interventions in the NOD Mouse and Implications for Translation
Shoda, L. K. M., Young, D. L., Ramanujan, S., Whiting, C. C., Atkinson, M. A., Bluestone, J. A., Eisenbarth, G. S., Mathis, D., Rossini, A. A., Campbell, S. E., et al. (2005) · Immunity · doi:10.1016/j.immuni.2005.08.002 · Cited by 317
Keymeulen, B., Walter, M., Mathieu, C., Kaufman, L., Gorus, F., Hilbrands, R., Vandemeulebroucke, E., Van de Velde, U., Crenier, L., De Block, C., et al. (2010) · Diabetologia · doi:10.1007/s00125-009-1644-9 · Cited by 317
Self-citationCD3-specific antibody-induced active tolerance: from bench to bedside
Chatenoud, L. (2003) · Nature Reviews Immunology · doi:10.1038/nri1000 · Cited by 309
Self-citationHunter, Z., McCarthy, D. P., Yap, W. T., Harp, C. T., Getts, D. R., Shea, L. D., & Miller, S. D. (2014) · ACS Nano · doi:10.1021/nn405033r · Cited by 301
The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes
Pearson, J. A., Wong, F. S., & Wen, L. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.08.019 · Cited by 298
Bresson, D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27191 · Cited by 293
Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease
Miller, S. D., Turley, D. M., & Podojil, J. R. (2007) · Nature Reviews Immunology · doi:10.1038/nri2153 · Cited by 290
Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis
Czaja, A. J., & Manns, M. P. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.053 · Cited by 280
Teplizumab and β-cell function in newly diagnosed type 1 diabetes
Ramos, E. L., Dayan, C. M., Chatenoud, L., Sumnik, Z., Simmons, K. M., Szypowska, A., Gitelman, S. E., Knecht, L. A., Niemoeller, E., Tian, W., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308743 · Cited by 273
Self-citationType 1 diabetes as a relapsing–remitting disease?
von Herrath, M., Sanda, S., & Herold, K. (2007) · Nature Reviews Immunology · doi:10.1038/nri2192 · Cited by 270
Smith, T. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002469 · Cited by 267
New frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
“Additionally, a preclinical study in the NOD mouse during the 1990s showed a short course of an anti-CD3 mAb could reverse and induce long term remission of autoimmune diabetes (Chatenoud et al., 1994), a finding that created the foundation for anti-CD3 mAb translation into T1D.”
BackgroundTeplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes
Hagopian, W., Ferry, R. J., Sherry, N., Carlin, D., Bonvini, E., Johnson, S., Stein, K. E., Koenig, S., Daifotis, A. G., Herold, K. C., et al. (2013) · Diabetes · doi:10.2337/db13-0236 · Cited by 247
Sherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., & Herold, K. C. (2007) · Endocrinology · doi:10.1210/en.2007-0358 · Cited by 169
“(32) and recently reported by our group (18, 31).”
BackgroundBeta cell mass in diabetes: a realistic therapeutic target?
Meier, J. J. (2008) · Diabetologia · doi:10.1007/s00125-008-0936-9 · Cited by 155
Vukmanovic-Stejic, M., Agius, E., Booth, N., Dunne, P. J., Lacy, K. E., Reed, J. R., Sobande, T. O., Kissane, S., Salmon, M., Rustin, M. H., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35834 · Cited by 131
Changing the landscape for type 1 diabetes: the first step to prevention
Dayan, C. M., Korah, M., Tatovic, D., Bundy, B. N., & Herold, K. C. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32127-0 · Cited by 96
Grijse, D. (2010) · doi:10.1007/s00125-009-1618-y · Cited by 94
Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials
Staeva, T. P., Chatenoud, L., Insel, R., & Atkinson, M. A. (2013) · Diabetes · doi:10.2337/db12-0562 · Cited by 91
Self-citationAnti-CD3 antibodies for type 1 diabetes: beyond expectations
Bach, J.-F. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60980-x · Cited by 59
Self-citationImmune intervention in type 1 diabetes
Michels, A. W., & Eisenbarth, G. S. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.07.003 · Cited by 47
Evolving antibody therapies for the treatment of type 1 diabetes
Ke, Q., Kroger, C. J., Clark, M., & Tisch, R. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624568 · Cited by 44
A historical view from thirty eventful years of immunotherapy in autoimmune diabetes
Bach, J.-F., & Chatenoud, L. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.07.009 · Cited by 41
Self-citationTargeting Memory T Cells in Type 1 Diabetes
Ehlers, M. R., & Rigby, M. R. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0659-5 · Cited by 40
Evaluating Preclinical Efficacy
Atkinson, M. A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002757 · Cited by 39
New therapeutic approaches for type 1 diabetes: Disease-modifying therapies
Nagy, G., Szekely, T. E., Somogyi, A., Herold, M., & Herold, Z. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i10.835 · Cited by 23
Regulatory T Cells: Central Concepts from Ontogeny to Therapy
Khor, B. (2017) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2016.07.003 · Cited by 15
“Treatment with anti-CD3 increases pTreg induction and induces remission of autoimmune diabetes in mice [70,71].”
Background
Metadata
- Authors
- Chatenoud, L., Thervet, E., Primo, J., & Bach, J. F.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1994-01-04
- Volume
- 91
- Issue
- 1
- Pages
- 123-127
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2057043713
- Cited by
- 664
- References
- 20
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.